What is STLN's Value Score?

Starling Oncology, Inc. - Common Stock (STLN) has a StockPik Value Score of 50 out of 100 — a mid-range score, indicating moderate value characteristics. The Value Score is a composite ranking built from P/E ratio, P/B ratio, Graham Number, ROE, gross margin, debt-to-equity, current ratio, and Piotroski F-Score, calculated from SEC EDGAR annual filing data.

What is STLN's Piotroski F-Score?

Starling Oncology, Inc. - Common Stock (STLN) has a Piotroski F-Score of 4 out of 9 — a moderate score. The F-Score assesses nine binary financial criteria across profitability, leverage, and operating efficiency. A score of 7–9 indicates a financially improving company; a score of 0–3 is a warning sign.

What is STLN's Piotroski F-Score?

STLN's Piotroski F-Score is 4 out of 9, indicating moderate financial health. The Piotroski F-Score evaluates nine criteria across profitability, leverage, and operating efficiency. Scores of 7 or above are considered strong; 3 or below indicate financial weakness.

Is STLN (Starling Oncology, Inc. - Common Stock) undervalued?

STLN scores 50/100 on StockPik's Value Score, an above-average rating.

Back to Screener

Starling Oncology, Inc. - Common Stock (STLN)

NASDAQ Small Cap

$6.16

Market Cap: $628M

Data as of Jun 30, 2026 (TTM)

Investment Snapshot

Piotroski F-Score 4/9 — moderate financial health
Negative net margin (-8.1%) — currently unprofitable
Revenue growing at 28% annually

Starling Oncology, Inc. - Common Stock (STLN) is a publicly traded company, listed on the NASDAQ , with a market capitalisation of $628 million . Key value metrics: Piotroski F-Score 4 out of 9 (moderate financial health) .

Value Score

out of 100

Try PRO Free — See Full Breakdown

Key Metrics

P/E Ratio

—

P/B Ratio

—

EPS

$-0.45

Div. Yield

—

PEG Ratio

—

P/S Ratio

—

EV/EBITDA

—

ROE

—

ROA

—

Gross Margin

—

Op. Margin

—

Net Margin

—

Debt/Equity

—

Current Ratio

—

Unlock 19 More Metrics — 7 Days Free

Data sourced from SEC EDGAR and Polygon.io. Methodology.

Starling Oncology, Inc. - Common Stock — Fundamental Analysis Summary

StockPik's composite Value Score for STLN is 50/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

STLN shows revenue growing at 28% year-over-year, with earnings growing at 6%.

How is the Value Score calculated?

Read our full methodology →

What is the Piotroski F-Score?

The 9-point financial health score explained, with worked examples →

STLD — Steel Dynamics, Inc. - Common Stock

STMicroelectronics N.V. Common Stock — STM